Tivic Health Systems, Inc.(TIVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TIVC Tivic Health Systems, Inc.

Market Closed 01-30 16:00:00 EST

1.19

-0.04

-3.25%

盘后1.19

+0.000.00%

18:28 EST

High1.25	Low1.17	Vol40.98K
Open1.23	D1 Closing1.23	Amplitude6.50%
Mkt Cap3.01M	Tradable Cap2.77M	Total Shares2.53M
T/O49.32K	T/O Rate1.76%	Tradable Shares2.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TIVC","market":"US","secType":"STK","nameCN":"Tivic Health Systems, Inc.","latestPrice":1.19,"timestamp":1769806800000,"preClose":1.23,"halted":0,"volume":40980,"hourTrading":{"tag":"盘后","latestPrice":1.19,"preClose":1.19,"latestTime":"18:28 EST","volume":201,"amount":239.57,"timestamp":1769815734230,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.032520325203252064,"floatShares":2329400,"shares":2525778,"eps":-9.300235,"marketStatus":"Market Closed","change":-0.04,"latestTime":"01-30 16:00:00 EST","open":1.23,"high":1.25,"low":1.17,"amount":49319.958642,"amplitude":0.065041,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.300235,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770022800000},"marketStatusCode":7,"adr":0,"listingDate":1636606800000,"exchange":"NASDAQ","adjPreClose":1.23,"preHourTrading":{"tag":"盘前","latestPrice":1.2782,"preClose":1.23,"latestTime":"08:00 EST","volume":800,"amount":990.05832,"timestamp":1769778019049,"change":0.0482,"changeRate":0.039187,"amplitude":0.081301},"postHourTrading":{"tag":"盘后","latestPrice":1.19,"preClose":1.19,"latestTime":"18:28 EST","volume":201,"amount":239.57,"timestamp":1769815734230,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.39141014507004124},"requestUrl":"/m/hq/s/TIVC","defaultTab":"news","newsList":[{"id":"2606030711","title":"Tivic Health Presents Entolimod Data at BARDA TechWatch Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2606030711","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606030711?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:30","pubTimestamp":1769607039,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc. delivered an invited presentation at a TechWatch meeting with the Biomedical Advanced Research and Development Authority , along with members of the Department of Defense, Defense Threat Reduction Agency, National Institutes of Health, and National Institute of Allergy and Infectious Diseases. During the event, Tivic showcased clinical and manufacturing readiness data for its Toll-like Receptor 5  agonist, Entolimod, highlighting its potential as a radiation countermeasure and its accelerated development through subsidiary Velocity Bioworks. The presentation initiated discussions about the possible inclusion of Entolimod in the Strategic National Stockpile, with BARDA requesting a follow-up meeting to further explore its utility.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL7gfkfz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2606241319","title":"Tivic Health Showcases Entolimod Commercialization Strategy at DealFlow Discovery Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2606241319","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606241319?lang=en_us&edition=fundamental","pubTime":"2026-01-26 23:10","pubTimestamp":1769440214,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc. will present at the 3rd Annual DealFlow Discovery Conference, taking place on January 28-29, 2026, at The Borgata Hotel, Casino & Spa in Atlantic City, New Jersey. The company’s CEO is scheduled to provide updates on key milestones, including Entolimod cell line verification, manufacturing scale-up, and the integration of Velocity Bioworks to accelerate commercial readiness. The presentation will also cover Tivic’s engagement with BARDA and progress toward a Biologics License Application submission. Investors interested in meeting Tivic’s management team can request a no-cost investor pass to attend the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL9MQmrn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2605895147","title":"Tivic Health CEO to Present Corporate Update at Emerging Growth Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2605895147","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605895147?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:50","pubTimestamp":1768949455,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc. will participate in the Emerging Growth Virtual Conference on January 22, 2026. CEO Jennifer Ernst is scheduled to provide a corporate update from 4:10 to 4:20 Eastern Time, highlighting recent milestones such as the acceleration of manufacturing readiness for Entolimod and the integration of Velocity Bioworks to expand in-house manufacturing capabilities. An archived webcast of the presentation will be available for those unable to attend live.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire  on January 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL6bC55c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIVC","BK4082"],"gpt_icon":0},{"id":"2602499715","title":"Tivic Health delivers 200x scale-up in manufacturing for entolimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2602499715","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602499715?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:50","pubTimestamp":1768229450,"startTime":"0","endTime":"0","summary":"Tivic Health (TIVC) delivered a 200x scale-up in manufacturing volume for Tivic’s lead drug candidate Entolimod. Entolimod is a TLR5 agonist in dev...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tivic-health-delivers-200x-scale-up-in-manufacturing-for-entolimod-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tivic-health-delivers-200x-scale-up-in-manufacturing-for-entolimod-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2602273543","title":"Tivic Health Scales Up Entolimod Manufacturing with Velocity Bioworks Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2602273543","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602273543?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:01","pubTimestamp":1768226488,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc. has announced a significant expansion in its manufacturing capabilities following the acquisition of certain CDMO assets, now branded as Velocity Bioworks. This move has enabled Tivic to achieve a 200-fold scale-up in the production of its lead drug candidate, Entolimod, a TLR5 agonist under development for Acute Radiation Syndrome  and Neutropenia. The company has successfully demonstrated commercial-scale production and is preparing to initiate manufacturing under current Good Manufacturing Practice  conditions, marking a key step toward filing a Biologics License Application with the FDA. The expansion is expected to enhance operational and cost efficiencies and accelerate the path to commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL5qfJp9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2601629103","title":"Tivic Health Acquires CDMO Assets to Accelerate Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2601629103","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601629103?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:30","pubTimestamp":1767879044,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc. has provided an update on its recent acquisition of certain contract development and manufacturing organization  assets, now branded as Velocity Bioworks. According to the company, the integration of these assets has already led to lower costs, reduced outsourcing delays, and accelerated the validation of the manufacturing process for Entolimod. Tivic believes this move will allow it to submit a biologics license application to the U.S. Food and Drug Administration ahead of schedule. Additionally, Velocity Bioworks is now operating as a stand-alone CDMO, offering fast, high-quality biologic production services to third-party customers, particularly targeting small and medium-sized development-stage biotechnology companies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL7zrDL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIVC","BK4082"],"gpt_icon":0},{"id":"2595753774","title":"Tivic Health Systems Inc. Announces Date for Upcoming Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2595753774","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595753774?lang=en_us&edition=fundamental","pubTime":"2025-12-30 06:09","pubTimestamp":1767046154,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc. has announced that it will hold a Special Meeting of Stockholders on February 19, 2026. At the meeting, stockholders will vote on several proposals, including the adjournment of the Special Meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL59FbXn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2590140905","title":"Tivic Health Secures $16M Debt Financing Led by 3i for Manufacturing Asset Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2590140905","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590140905?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:46","pubTimestamp":1765464366,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc. has secured a new financing package led by 3i, LP to support its recent acquisition of manufacturing and development assets. The agreement includes $16 million in debt financing designated for the purchase of assets, equipment, and facility improvements. Additionally, Tivic has access to up to $75 million in preferred convertible equity, with $18 million available in two near-term tranches and the remainder at the company's discretion, subject to certain conditions. An affiliate of 3i, LP is also expected to provide Tivic with a $50 million equity line of credit to further support its growth initiatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content use","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL6LbT1z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIVC","BK4082"],"gpt_icon":0},{"id":"2584688369","title":"Tivic Health Shares Rise After US Agency Meeting on Entolimod Set","url":"https://stock-news.laohu8.com/highlight/detail?id=2584688369","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584688369?lang=en_us&edition=fundamental","pubTime":"2025-11-19 03:19","pubTimestamp":1763493578,"startTime":"0","endTime":"0","summary":"Tivic Health Systems (TIVC) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiolo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2584959560","title":"Tivic Health secures BARDA meeting for entolimod in ARS","url":"https://stock-news.laohu8.com/highlight/detail?id=2584959560","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584959560?lang=en_us&edition=fundamental","pubTime":"2025-11-18 23:10","pubTimestamp":1763478624,"startTime":"0","endTime":"0","summary":"Tivic Health (TIVC) Systems has secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority’s Radiologic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tivic-health-secures-barda-meeting-for-entolimod-in-ars-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tivic-health-secures-barda-meeting-for-entolimod-in-ars-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2583871696","title":"Tivic Health Systems Shifts Focus to Biopharma Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2583871696","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583871696?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:18","pubTimestamp":1763158702,"startTime":"0","endTime":"0","summary":"Tivic Health Systems ( ($TIVC) ) just unveiled an announcement. On November 12, 2025, Tivic Health Systems‘ board decided to wind down its ClearUP ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tivic-health-systems-shifts-focus-to-biopharma-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tivic-health-systems-shifts-focus-to-biopharma-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2583682994","title":"Tivic Health Systems Q3 EPS $(2.00) Up From $(3.93) YoY, Sales $146.000K Up From $126.000K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682994","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682994?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:49","pubTimestamp":1763156957,"startTime":"0","endTime":"0","summary":"Tivic Health Systems (NASDAQ:TIVC) reported quarterly losses of $(2.00) per share. This is a 49.11 percent increase over losses of $(3.93) per share from the same period last year.  The company reported $146.000 thousand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48882113/tivic-health-systems-q3-eps-2-00-up-from-3-93-yoy-sales-146-000k-up-from-126-000k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tivic Health Systems Q3 EPS $(2.00) Up From $(3.93) YoY, Sales $146.000K Up From $126.000K YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIVC"],"gpt_icon":0},{"id":"2583828426","title":"Bioelectronic medicine maker Tivic Health's Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2583828426","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583828426?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:39","pubTimestamp":1763156387,"startTime":"0","endTime":"0","summary":"Bioelectronic medicine maker Tivic Health's Q3 net loss widensOverviewTivic Health Q3 revenue rises to $146,000, final quarter for direct ClearUP salesNet loss widens to $2.6 mln in Q3, impacted by co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ14X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2583477684","title":"BRIEF-Tivic Health Systems Q3 Net Income USD -2.596 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583477684","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583477684?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:30","pubTimestamp":1763155846,"startTime":"0","endTime":"0","summary":"BRIEF-Tivic Health Systems Q3 Net Income USD -2.596 Million\n\n\nNov 14 (Reuters) - Tivic Health Systems Q3 operating expenses USD 2.338 million.\n\nQ3 revenue USD 146 thousand\nQ3 gross profit USD -145 thousand\nQ3 operating income USD -2.483 million\nQ3 basic EPS USD -1.97","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX0B7D80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2583168421","title":"Tivic Health Reports Q3 2025 Results and Advances Entolimod Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2583168421","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583168421?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:30","pubTimestamp":1763155834,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc. announced its financial results for the third quarter and nine months ended September 30, 2025. The company reported continued progress in its strategic transformation and advancement of its biologics pipeline. During the quarter, Tivic completed the transfer of two Investigational New Drug  applications from Statera Biopharma, enabling the company to conduct clinical trials in neutropenia and lymphocyte exhaustion, and to explore Entolimod's anti-tumor activity for potential cancer-related indications. The company also finalized cell line verification, a critical step to enable Current Good Manufacturing Practices , required before filing a biologics license application  with the U.S. Food & Drug Administration. Tivic advanced the wind down of its consumer health technology business, discontinued significant resource allocation to ClearUP sales, and wrote off related inventory during the quarter. The company launched a new corporate website reflecting its upd","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL9HQrzH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4082","STAB","TIVC"],"gpt_icon":0},{"id":"2583684479","title":"Tivic Health Systems Q3 Gross Profit USD -145 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2583684479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583684479?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:30","pubTimestamp":1763155801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX0B7D80:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2583159358","title":"Tivic Health Optimizes Personalized Vagus Nerve Stimulation in New Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2583159358","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583159358?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040629,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc. has announced findings from a clinical optimization trial of its non-invasive cervical vagus nerve stimulation  technology, conducted in collaboration with The Feinstein Institutes for Medical Research at Northwell Health. The study demonstrated that personalizing stimulation parameters, such as frequency, amplitude, electrode positioning, and duration, significantly enhanced autonomic effects in healthy subjects. Specifically, tailoring the frequency of ncVNS to each individual led to a 46% increase in heart rate variability and was nearly nine times more effective than using a uniform frequency across all subjects. The results also indicated that optimal stimulation frequency varied between sessions and that electrode placement played a critical role in outcomes. Additionally, a four-minute stimulation period was found to be more effective than a twenty-minute session. Tivic Health stated that these results advance the understanding of neurostimulation and m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL3hLwfk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2582877271","title":"Tivic files patent applications for cancer therapy, nerve stimulation device","url":"https://stock-news.laohu8.com/highlight/detail?id=2582877271","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582877271?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:20","pubTimestamp":1762784434,"startTime":"0","endTime":"0","summary":"Tivic Health (TIVC) announced it is expanding its intellectual property portfolio with the recent filing of two additional patent applications with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tivic-files-patent-applications-for-cancer-therapy-nerve-stimulation-device-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tivic-files-patent-applications-for-cancer-therapy-nerve-stimulation-device-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","TIVC"],"gpt_icon":0},{"id":"2581094893","title":"Press Release: Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2581094893","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581094893?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:31","pubTimestamp":1762439460,"startTime":"0","endTime":"0","summary":"Tivic Health Systems, Inc. , a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET.Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system.Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track and Orphan Drug designations and is in late-stage development.Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may re","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4082","BK4555","BK4585","BK4588","BK4232","R","TM","TIVC","03160","BK4604","BK4099"],"gpt_icon":0},{"id":"2577390698","title":"Tivic Health CEO Jennifer Ernst to Join Panel at Northwell Health Innovation Constellation Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2577390698","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577390698?lang=en_us&edition=fundamental","pubTime":"2025-10-23 02:00","pubTimestamp":1761156016,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc. CEO Jennifer Ernst will participate in the 8th Annual Northwell Health Innovation Constellation Forum on Thursday, October 23. She will join a panel titled \"Building a Big Tent\" to discuss opportunities for advancing bioelectronic medicine and strategies for fostering collaboration across the healthcare ecosystem.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire  on October 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL1HQ5vS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","TIVC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tivichealth.com","stockEarnings":[{"period":"1week","weight":-0.048},{"period":"1month","weight":-0.1793},{"period":"3month","weight":-0.5259},{"period":"6month","weight":-0.6304},{"period":"1year","weight":-0.7083},{"period":"ytd","weight":-0.1793}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.0145},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1437},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.211447},{"month":2,"riseRate":0.5,"avgChangeRate":-0.017023},{"month":3,"riseRate":0.25,"avgChangeRate":-0.224592},{"month":4,"riseRate":0.25,"avgChangeRate":0.101952},{"month":5,"riseRate":0.25,"avgChangeRate":-0.192215},{"month":6,"riseRate":0.5,"avgChangeRate":0.020107},{"month":7,"riseRate":0.5,"avgChangeRate":-0.032199},{"month":8,"riseRate":0,"avgChangeRate":-0.290194},{"month":9,"riseRate":0,"avgChangeRate":-0.210672},{"month":10,"riseRate":0.5,"avgChangeRate":-0.035466},{"month":11,"riseRate":0.25,"avgChangeRate":0.035875},{"month":12,"riseRate":0.4,"avgChangeRate":-0.08786}],"exchange":"NASDAQ","name":"Tivic Health Systems, Inc.","nameEN":"Tivic Health Systems, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tivic Health Systems, Inc.(TIVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tivic Health Systems, Inc.(TIVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tivic Health Systems, Inc.,TIVC,Tivic Health Systems, Inc.股票,Tivic Health Systems, Inc.股票老虎,Tivic Health Systems, Inc.股票老虎国际,Tivic Health Systems, Inc.行情,Tivic Health Systems, Inc.股票行情,Tivic Health Systems, Inc.股价,Tivic Health Systems, Inc.股市,Tivic Health Systems, Inc.股票价格,Tivic Health Systems, Inc.股票交易,Tivic Health Systems, Inc.股票购买,Tivic Health Systems, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tivic Health Systems, Inc.(TIVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tivic Health Systems, Inc.(TIVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction